-
- Clara García-Carro
- Nephrology Department, San Carlos Clinical University Hospital, 28040 Madrid, Spain
-
- Ander Vergara
- Nephrology Research Group, Nephrology Department, Vall d’Hebrón Research Institute (VHIR), Vall d’Hebron Barcelona Hospital Campus, Vall d’Hebrón Hospital Universitari, 08035 Barcelona, Spain
-
- Sheila Bermejo
- Nephrology Research Group, Nephrology Department, Vall d’Hebrón Research Institute (VHIR), Vall d’Hebron Barcelona Hospital Campus, Vall d’Hebrón Hospital Universitari, 08035 Barcelona, Spain
-
- María A. Azancot
- Nephrology Research Group, Nephrology Department, Vall d’Hebrón Research Institute (VHIR), Vall d’Hebron Barcelona Hospital Campus, Vall d’Hebrón Hospital Universitari, 08035 Barcelona, Spain
-
- Ana I. Sánchez-Fructuoso
- Nephrology Department, San Carlos Clinical University Hospital, 28040 Madrid, Spain
-
- M. Dolores Sánchez de la Nieta
- Nephrology Department, San Carlos Clinical University Hospital, 28040 Madrid, Spain
-
- Irene Agraz
- Nephrology Research Group, Nephrology Department, Vall d’Hebrón Research Institute (VHIR), Vall d’Hebron Barcelona Hospital Campus, Vall d’Hebrón Hospital Universitari, 08035 Barcelona, Spain
-
- María José Soler
- Nephrology Research Group, Nephrology Department, Vall d’Hebrón Research Institute (VHIR), Vall d’Hebron Barcelona Hospital Campus, Vall d’Hebrón Hospital Universitari, 08035 Barcelona, Spain
説明
<jats:p>Diabetic kidney disease (DKD) is one of the most relevant complications of type 2 diabetes and dramatically increases the cardiovascular risk in these patients. Currently, DKD is severely infra-diagnosed, or its diagnosis is usually made at advanced stages of the disease. During the last decade, new drugs have demonstrated a beneficial effect in terms of cardiovascular and renal protection in type 2 diabetes, supporting the crucial role of an early DKD diagnosis to permit the use of new available therapeutic strategies. Moreover, cardiovascular and renal outcome trials, developed to study these new drugs, are based on diverse cardiovascular and renal simple and composite endpoints, which makes difficult their interpretation and the comparison between them. In this article, DKD diagnosis is reviewed, focusing on albuminuria and the recommendations for glomerular filtration rate measurement. Furthermore, cardiovascular and renal endpoints used in classical and recent cardiovascular outcome trials are assessed in a pragmatic way.</jats:p>
収録刊行物
-
- Journal of Clinical Medicine
-
Journal of Clinical Medicine 10 (11), 2505-, 2021-06-05
MDPI AG